DE60326833D1 - Vitamin mitomycin-conjugate - Google Patents

Vitamin mitomycin-conjugate

Info

Publication number
DE60326833D1
DE60326833D1 DE2003626833 DE60326833A DE60326833D1 DE 60326833 D1 DE60326833 D1 DE 60326833D1 DE 2003626833 DE2003626833 DE 2003626833 DE 60326833 A DE60326833 A DE 60326833A DE 60326833 D1 DE60326833 D1 DE 60326833D1
Authority
DE
Grant status
Grant
Patent type
Prior art keywords
mitomycin
vitamin
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2003626833
Other languages
German (de)
Inventor
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
DE2003626833 2002-05-15 2003-05-13 Vitamin mitomycin-conjugate Active DE60326833D1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US38057902 true 2002-05-15 2002-05-15
US42591802 true 2002-11-13 2002-11-13
PCT/US2003/014969 WO2003097647A1 (en) 2002-05-15 2003-05-13 Vitamin-mitomycin conjugates

Publications (1)

Publication Number Publication Date
DE60326833D1 true DE60326833D1 (en) 2009-05-07

Family

ID=29553501

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2003626833 Active DE60326833D1 (en) 2002-05-15 2003-05-13 Vitamin mitomycin-conjugate

Country Status (8)

Country Link
US (1) US7910594B2 (en)
EP (2) EP2060272A3 (en)
JP (1) JP4814520B2 (en)
KR (1) KR20040106547A (en)
CA (1) CA2484640C (en)
DE (1) DE60326833D1 (en)
ES (1) ES2324708T3 (en)
WO (1) WO2003097647A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60326833D1 (en) 2002-05-15 2009-05-07 Endocyte Inc Vitamin mitomycin-conjugate
CN100381177C (en) 2003-01-27 2008-04-16 恩多塞特公司 Vitamin receptor binding drug delivery conjugates
CN101098854B (en) * 2004-07-23 2012-12-05 恩多塞特公司 Bivalent linkers and conjugates thereof
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
CA2595517C (en) 2004-12-22 2013-09-24 Sapporo Medical University Drug carrier and drug carrier kit for inhibiting fibrosis
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
DE602006012816D1 (en) 2005-03-30 2010-04-22 Endocyte Inc Tification of cellular folate vitamin receptors
CA2617660C (en) * 2005-08-19 2014-03-25 Endocyte, Inc. Multi-drug ligand conjugates
WO2007022493A3 (en) * 2005-08-19 2008-01-24 Endocyte Inc Ligand conjugates of vinca alkaloids, analogs, and derivatives
EP1832575A1 (en) * 2006-03-06 2007-09-12 Sulfidris S.r.l. Anti-inflammatory agents
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101970012A (en) * 2007-09-14 2011-02-09 日东电工株式会社 Drug carriers
JP2009221164A (en) 2008-03-17 2009-10-01 Nitto Denko Corp Drug for treating pulmonary fibrosis
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP5950428B2 (en) 2010-08-05 2016-07-13 日東電工株式会社 Composition for regenerating normal tissue from fibrotic tissue
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
JP6340162B2 (en) 2012-12-20 2018-06-06 日東電工株式会社 Apoptosis-inducing agents
CA2944417A1 (en) 2014-04-02 2015-10-08 Nitto Denko Corporation A targeting molecule and a use thereof
US20180071253A1 (en) * 2015-03-17 2018-03-15 Lipomedix Pharmaceuticals Ltd. Methods for the treatment of bladder cancer
EP3280454A1 (en) 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515483A (en) * 1946-08-10 1950-07-18 Merck & Co Inc Diacylated pteroic acid and process for preparing same
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US3392173A (en) * 1964-03-09 1968-07-09 Lilly Co Eli Novel acyl derivatives of desacetyl-vincaleukoblastine and processes for their preparation
US3387001A (en) * 1964-10-19 1968-06-04 Lilly Co Eli Novel aminoacyl esters of desacetyl vincaleukoblastine
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4166810A (en) * 1978-04-20 1979-09-04 Eli Lilly And Company Derivatives of 4-desacetyl VLB C-3 carboxyhydrazide
US4337339A (en) * 1979-04-30 1982-06-29 Baker Instruments Corp. Process for preparation of folic acid derivatives
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
DE3376114D1 (en) 1982-12-07 1988-05-05 Kyowa Hakko Kogyo Kk Mitomycin analogues
JPH0358349B2 (en) 1983-03-25 1991-09-05 Kyowa Hakko Kogyo Kk
US4866180A (en) * 1984-02-24 1989-09-12 Bristol-Myers Company Amino disulfide thiol exchange products
JPS60255789A (en) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd Mitomycin derivative, its preparation, and antitumor agent
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
DE3750846D1 (en) 1986-08-29 1995-01-19 Kyowa Hakko Kogyo Kk Mitomycin derivatives.
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5094849A (en) * 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
CA2044590A1 (en) 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5998603A (en) * 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
EP0547163B1 (en) * 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
DE69430060T2 (en) * 1993-04-23 2002-11-07 Abbott Lab Antibodies of rapamycins with open ring
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6171859B1 (en) * 1994-03-30 2001-01-09 Mitokor Method of targeting conjugate molecules to mitochondria
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US6177404B1 (en) * 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
DE19621133A1 (en) * 1996-05-24 1997-11-27 Boehringer Mannheim Gmbh Determination method with oligomerized receptors
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6291684B1 (en) * 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
KR100669053B1 (en) * 1999-04-23 2007-01-15 알자 코포레이션 Conjugate having a cleavable linkage for use in a liposome
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7033594B2 (en) * 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) * 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
EP2316976A1 (en) * 2000-11-28 2011-05-04 Wyeth LLC Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002079499A1 (en) * 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
CA2449077A1 (en) * 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
KR20040036913A (en) * 2001-07-31 2004-05-03 이뮤노메딕스, 인코오포레이티드 Targeted Polymeric Delivery Systems
ES2246409T3 (en) * 2001-08-22 2006-02-16 Wyeth Rapamycin 29-enols.
WO2003018574A1 (en) * 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
EP1434603B1 (en) * 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
CA2464271A1 (en) * 2001-10-22 2003-05-01 The Scripps Research Institute Integrin targeting compounds
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US7000695B2 (en) * 2002-05-02 2006-02-21 Halliburton Energy Services, Inc. Expanding wellbore junction
ES2500922T3 (en) * 2002-05-06 2014-10-01 Endocyte, Inc. Forming agents targeted folate receptor images
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
DE60326833D1 (en) 2002-05-15 2009-05-07 Endocyte Inc Vitamin mitomycin-conjugate
WO2004032877A3 (en) * 2002-10-10 2005-10-06 Wei Liu Compositions, organisms and methodologies employing a novel human kinase
DE10254439A1 (en) * 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysins, manufacturing methods and means tubulysin
EP1578197A4 (en) * 2002-11-21 2006-05-17 Wyeth Corp Composition and method for treating lupus nephritis
EP2660322A3 (en) * 2003-04-17 2013-11-13 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2004101803A3 (en) * 2003-05-12 2005-02-17 Valerie Sue Bernan Process for producing anticancer agent ll-d45042
WO2005010010A1 (en) * 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
ES2287772T3 (en) * 2003-08-07 2007-12-16 Wyeth regioselective synthesis of CCI-779.
WO2006020768A3 (en) * 2004-08-10 2007-07-05 Alnylam Pharmaceuticals Inc Chemically modified oligonucleotides
US7290958B2 (en) * 2004-12-03 2007-11-06 Airfield Systems, Llc Subsurface drainage system and drain structure therefor
DE602006012816D1 (en) 2005-03-30 2010-04-22 Endocyte Inc Tification of cellular folate vitamin receptors
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease

Also Published As

Publication number Publication date Type
EP2060272A2 (en) 2009-05-20 application
CA2484640A1 (en) 2003-11-27 application
US7910594B2 (en) 2011-03-22 grant
WO2003097647A1 (en) 2003-11-27 application
EP1504010A1 (en) 2005-02-09 application
JP4814520B2 (en) 2011-11-16 grant
EP1504010B1 (en) 2009-03-25 grant
ES2324708T3 (en) 2009-08-13 grant
US20050165227A1 (en) 2005-07-28 application
KR20040106547A (en) 2004-12-17 application
CA2484640C (en) 2012-01-17 grant
EP2060272A3 (en) 2009-05-27 application
EP1504010A4 (en) 2007-03-28 application
JP2005531564A (en) 2005-10-20 application

Similar Documents

Publication Publication Date Title
DE50303317D1 (en) Slide-switches
DE50302138D1 (en) O-frame-mold
DE10215877B4 (en) Eckfräswerkzeug
DE50300477D1 (en) Falzschwertantrieb
DE50212349D1 (en) Hirurgie
DE50301791D1 (en) Sockenanzieher

Legal Events

Date Code Title Description
8364 No opposition during term of opposition